Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Van der Niepen, P.
Right arrow Articles by Verbeelen, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van der Niepen, P.
Right arrow Articles by Verbeelen, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (1995) 10: 2253-2258
© 1995 European Renal Association-European Dialysis and Transplant Association

research-article

Effect of treatment with 1.25 and 1.75 mmol/l calcium dialysate on bone mineral density in haemodialysis patients

P. Van der Niepen1,, J. Sennesael2, O. Louis2 and D. Verbeelen1

1Section of Nephrology, Dept of Medicine, Academisch Ziekenhuis, Vrije Universiteit Brussel Belgium 2Dept of Radiology, Academisch Ziekenhuis, Vrije Universiteit Brussel Belgium

Correspondence and offprint requests to: Correspondence and offprint requests to: D. Verbeelen, Section of Nephrology, Dept of Medicine, Academisch Ziekenhuis, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090 Brussel, Belgium

The effect of two different dialysate solutions with a calcium concentration of 1.25 and 1.75 mmol/l was evaluated in 14 patients, using a cross-over design. Patients were treated with each solution during a period of 6 months. Treatment with calcium supplements, vitamin D and aluminium hydroxide was adapted weekly, according to the results of blood chemistry. PTH, SAP, and ionized calcium were determined monthly, bone density with DXA and QCT before and after 6 months of treatment. During treatment with both 1.25 and 1.75 calcium dialysate (cad), the control of serum calcium and phosphate was similar. PTH did not change during either treatment. SAP decreased during treatment with 1.75, but remained stable with 1.25 mmol/1 cad. Bone density evaluated with DXA remained unchanged during both treatments. QCT measured bone density increased from 101.29± 13.50 to 106.79±13.14 mg/ml in the 1.75 cad group, while it did not vary in the 1.25 cad group, (107.75 ±13.48 versus 108.97 ±13.40 mg/ml). It is concluded that lowering the calcium content of the dialysate does not negatively influence the control of serum calcium and phosphate, nor does it aggravate hyper-parathyroidism when vitamin D is administered simultaneously. Under the present conditions, osteopenia and possibly bone mineralization improve only in the group dialysed with 1.75 Ca.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.